IQVIA Holdings (IQV) has drawn fresh investor attention after reporting record net new bookings of US$3.2b in its research and development solutions unit, representing 19% year-over-year growth, alongside higher 2026 revenue and earnings guidance.

The recent operational update has coincided with strong momentum in IQVIA Holdings' stock, with a 16.21% 30-day share price return and a 42.81% 90-day share price return. The 1-year total shareholder return of 27.52% shows how that shorter-term strength compares with a more modest 12.75% total shareholder return over three years and a slightly negative 5-year total shareholder return, suggesting recent enthusiasm is building from a relatively softer longer-term base.

If record bookings in research and development have caught your eye, it could be a good moment to look at other life sciences data and drug development plays through our 44 healthcare AI stocks.

For IQVIA Holdings, the recent surge sits at the crossroads of stronger bookings and upgraded guidance on one side, and a catch up in sentiment after weaker long term returns on the other, which is where valuation comes in next.

Most Popular Narrative: 4.1% Overvalued

The most followed narrative currently places IQVIA Holdings' fair value at $232, slightly below the last close of $241.52, which frames the recent share price strength as a mild premium to those assumptions.

Continued investment in and deployment of proprietary platforms and agentic AI solutions, coupled with strategic collaborations and industry recognitions, increase switching costs and provide competitive barriers, positioning IQVIA to capture greater market share and support long-term revenue growth and margin improvement.

Want to see what sits behind that fair value? The narrative leans heavily on steady revenue compounding, firmer margins, and a future earnings multiple that assumes IQVIA keeps earning its place in life sciences data.

Result: Fair Value of $232 (OVERVALUED)

However, the IQVIA Holdings story could look different if pricing pressure in contract research and client delays on new projects begin to affect margins and revenue visibility.

Another View on IQVIA Holdings: Multiples Versus Fair Ratio

While the most popular narrative tags IQVIA Holdings as 4.1% overvalued at a fair value of $232, the preferred P/E work presents a more nuanced picture. At 28.9x, the stock trades below both peer averages of 35x and the global Life Sciences average of 37.8x, yet above its fair ratio of 26.7x. This relationship suggests the market could still drift closer to that lower anchor. How comfortable are you with paying a premium to the fair ratio while still sitting at a discount to peers?

Next Steps

Given the mixed sentiment around IQVIA Holdings, it makes sense to check the facts for yourself and move quickly to form your own view. To see both sides of the story in one place, take a closer look at the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond IQVIA Holdings?

IQVIA Holdings may already be on your radar, but some of the most compelling opportunities often sit just outside your current watchlist. Use these targeted stock ideas now so you do not miss potential standouts.

• Spot potential value opportunities early by checking companies that screen as 51 high quality undervalued stocks before they attract wider attention.
• Strengthen your portfolio's foundation by focusing on businesses highlighted in the solid balance sheet and fundamentals stocks screener (49 results) that aim for resilience when conditions get tougher.
• Hunt for underfollowed opportunities by reviewing the screener containing 18 high quality undiscovered gems where solid fundamentals may not yet be fully reflected in prices.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.